

PRODUCT THEATER

AN INVESTIGATIONAL NEW MOA THAT CAN STABILIZE THE INFLAMMATORY RESPONSE IN ULCERATIVE COLITIS



Parambir S. Dulai, MD

Director of GI Clinical Trials and Precision Medicine
Director of Digestive Health Foundation Biorepository
Associate Professor of Medicine
Northwestern University



2:30 - 2:40 PM

*Mechanism of Action of
Obefazimod*



2:40 - 2:50 PM

*Phase 2b Clinical Data of
Obefazimod in UC*



2:50 - 3:00 PM

*Overview of ABTECT
Clinical Trial Program*



3:00 - 3:15 PM


Q&A

JOIN US



Date :

Monday, May 20, 2024



Time :


2:30 - 3:15 PM



Location :

DDW Theater 1

QR code to access the
livestream and recording



ABIVAX

Obefazimod is an investigational medication and not approved by any health regulatory authority.

©2024 Abivax. All rights reserved. 04/2024